key: cord-0932329-ue6l0fds
authors: Metra, Brandon; Summer, Ross; Brooks, Sandra Elaine; George, Gautam; Sundaram, Baskaran
title: Racial disparities in COVID-19 associated pulmonary embolism: A multicenter cohort study
date: 2021-07-03
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.06.022
sha: af1e8ef04efb3d137140ad74f3e2537116a3b8a1
doc_id: 932329
cord_uid: ue6l0fds

BACKGROUND: Thromboembolism is a recognized component of severe coronavirus disease 2019 (COVID-19) disease. However, research into racial disparities in COVID-19-related pulmonary embolism is limited. MATERIALS AND METHODS: In this retrospective cohort study, we examined adults diagnosed with COVID-19 between January 20 and September 30, 2020, using a multicenter electronic health record dataset of over 73 million patients (TriNetX), mostly in the USA. The main study outcomes were development of pulmonary embolism or mortality within 30 days of COVID-19 diagnosis. Secondary outcome analysis included hospitalization, mechanical ventilation, and ICU admission within 30 days of diagnosis, as well as lab values within 0–1 days of diagnosis. Sociodemographic and clinical variables were used to create balanced cohorts via propensity matching. RESULTS: 346,953 patients were identified, with 56.0% non-Hispanic white and 14.7% non-Hispanic black; the mean age was 47.6 years. 3879 patients developed PE, with 2036 (1.30% of 157,049) white and 1088 (2.16% of 50,376) black patients. After propensity matching, black race was associated with higher mortality (risk ratio 1.890 [95% CI 1.727–2.067]) and PE (RR 1.537 [1.380–1.711]; p < 0.0001). Both races had higher mortality with COVID-associated PE than COVID or PE alone (RR 1.575–1.627 and 3.000–5.389 respectively; p < 0.0001). Black patients with COVID-19 and PE had a higher rate of mortality compared to white patients (RR 1.397 [1.059–1.844]; p = 0.0174). INTERPRETATION: Black race was associated with higher risk of pulmonary embolism and mortality after COVID-19. Additionally, black patients with COVID-19 and PE had a higher mortality compared to white patients.

Coronavirus disease , caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread worldwide with a global pandemic stage since March 2020, continuing to increase in the United States. Since the beginning of the pandemic, increasing data has highlighted racial disparities in the prevalence of COVID-19 in the United States. [1] [2] Thromboembolic events including pulmonary embolism (PE) are an increasingly recognized complication of COVID-19. [3, 4] [5, 6] Autopsy studies report widespread microthrombosis and endothelial injury within COVID-19-affected lung [7] , with these features more prominent in COVID-19 compared to other pulmonary infections. [8] Pulmonary embolism itself is a leading cause of cardiovascular death and morbidity [9] , with pre-COVID studies showing an increased incidence of thromboembolic disease in black individuals. [10, 11] Thus far, most published data on COVID-19 and PE consist of case series or singlecenter studies often with a focus specifically on critically ill patients. Differences in clinical characteristics and outcomes based on factors like age, gender, ethnicity, or pre-existing clinical comorbidities may not be fully reflected in these smaller data sets, emphasizing the importance of examining the effects of race on thromboembolic disease in the context of the COVID-19 pandemic in large patient cohorts. Therefore, we aimed to examine the effects of race on the event rate and outcomes of PE in patients with COVID-19 disease using a large multi-center global geographically and demographically diverse dataset, balancing their demographics and pre-existing conditions using propensity matching. This retrospective observational cohort study used the TriNetX COVID-19 Research Network, a federated global research network. [12] This network provides aggregated real-time data from the electronic health records (EHRs) of approximately 73 million patients over 56 health care organizations (HCOs), with the majority of these contained within the United States.

Each HCO consists of an integrated health care system, encompassing patients in emergency, inpatient, and outpatient care settings. Datasets from each HCO are processed by TriNetX as either de-identified or limited data. Within each HCO, patients are counted once, even if they received care at multiple locations within the HCO. As the TriNetX network uses aggregated counts of de-identified data without protected health information, it received a waiver from Western IRB. We compared characteristics of COVID-19 positive patients by race (non-Hispanic black vs. non-Hispanic white). To adjust for potential confounder variables and to facilitate comparison between cohorts, we performed propensity score matching. [13] Selected variables were identified using diagnosis codes and focused on demographics and common clinical comorbidities linked to pulmonary embolism, as detailed in the previous section. [9] A logistic regression model including demographic and comorbidity status for each patient generated a propensity score. Matching was then performed using greedy nearest neighbor matching with a caliper of 0.1 pooled standard deviations. Differences between groups before and after propensity matching were reported as standardized differences with corresponding p-values. A standardized mean difference of 0.1 or less was interpreted as a negligible difference in the mean or proportion of a covariate between the compared groups. [14] J o u r n a l P r e -p r o o f severe state of disease, as shown by higher inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate as well as lower oxygen saturation level. Additionally, we found an increased risk of 30-day mortality in black patients with COVID-19 and associated pulmonary embolism, compared to white patients; however, there was no significant difference in hospitalization, ICU admission, or mechanical ventilation.

Racial differences in the prevalence and severity of COVID-19 have been noted as the pandemic has unfolded in the United States, with black patients representing the majority of COVID-19 cases and having higher rates of comorbidities [1] , as well as higher prevalence and overall mortality rates. [16] Racial inequalities in general key health outcomes have long been known, with disproportionate effects falling upon African-American communities. Such disparities are wide-ranging, including prevalence of diabetes and obesity, mortality from J o u r n a l P r e -p r o o f cardiovascular disease, and overall life expectancy. [17] One possible explanation for the disparity in COVID-19 related outcomes is the higher rate of underlying comorbidities in black populations such as diabetes, hypertension, and obesity. [18] These comorbidities have been associated with higher risk of requiring hospitalization for COVID-19 infection [19] and have also been linked to higher risk for venous thromboembolism. [20] However, in our study, the higher mortality and pulmonary embolism rate persisted after propensity matching to control for these comorbidities.

An elevated risk for thromboembolic events in African-Americans has been seen before the COVID-19 pandemic, though the reasons are not fully understood. [21, 22] Studies have shown a higher prevalence of PE in blacks, despite lower prevalence of transient risk factors like surgery and trauma and classic genetic predispositions such as mutations in factor V Leiden and prothrombin. [21, 23] Other genetic factors may contribute to this disparity; for example, sickle cell trait (SCT) patients have higher risk for pulmonary embolism with or without associated deep venous thrombosis. [24] Additionally, studies have shown a higher D-Dimer in blacks with hypertension. [25] Higher D-Dimer in blacks has been associated with higher all-cause mortality, with underlying genetic explanation of HBB rs334 SCT locus as well as a variant of F3 locus, encoding tissue factor within the extrinsic coagulation pathway. [26] Finally, an autopsy series of black COVID-19 decedents in Louisiana observed diffuse alveolar damage and specifically pulmonary microangiopathy in all patients. [27] These findings suggest that blacks may be in a higher baseline prothrombotic state due to phenotypic and epigenetic variants, leaving them more vulnerable to COVID-19-associated coagulopathy.

Social disparities in access to health care may also help explain our observation of increased rate of PE in blacks with COVID-19. Social determinants such as housing environment, access to healthcare and healthy foods, and socioeconomic status are closely interlinked to health outcomes. In communities where adverse social determinants already are linked to poorer health outcomes, the tasks of social distancing and other prevention measures for COVID-19 become even more difficult. [28] Besides possible differences in thrombotic predisposition, many blacks may be presenting at a later, more severe stage within the course of COVID-19 disease. This would also contribute to the worse clinical outcomes and higher inflammatory markers, such as D-Dimer, seen within blacks with COVID-19 in our study.

Finally, while we were unable to analyze patients by ZIP code or city, black and white COVID-19 patients did have a different overall geographic distribution with proportionally more black patients located in the Southeast US. Corresponding geographic differences in social environment and healthcare access may also contribute to the differences seen in our analyses.

Limitations of our study include dependence on medical records data and aggregate nature of our dataset. First, while our data represents a large and diverse cohort of COVID-19 and comparison patients, it is based on direct EMR data aggregation. Such data may have limitations in coding or data entry, although the aggregation methods in real-time fashion limit data collection errors at the point of the study investigators. As our dataset is compiled in a deidentified manner from multiple health centers, a small number of patients may have crossed from one HCO to another in the course of their COVID-19 management; however, this would affect all cohorts equally and would reflect only a small fraction of our cohort, given that each individual HCO in TriNetX is a large integrated system comprised of many healthcare centers.

Additionally, inter-institutional differences in surveillance and treatment of PE may also be reflected within our observations. As this dataset tracks only patients seeking medical care, asymptomatic patients or patients unable to access health care could not be assessed. Due to the aggregate nature of our data, granular details such as severity of PE, severity of clinical comorbidities (e.g., degree of hypertension) or timing of symptoms could not be assessed. While we strived to control for clinical comorbidities and included homelessness as a socioeconomic variable, many socioeconomic details such as ZIP code of patient, type of health center, or patient income, were unavailable or limited within the de-identified nature of the TriNetX data; this limits our ability to assess the contribution of such socioeconomic factors to our findings.

Finally, laboratory values were not performed for all patients within the cohort, and therefore the roles of some lab parameters may be undervalued.

Overall, we hope that these findings will help inform interventions to mitigate the impact of COVID-19 upon vulnerable communities. A greater understanding of potential underlying genetic and environmental factors can help identify those at more inherent risk for severe thromboembolic disease. With a more granular understanding of such factors, clinicians can improve surveillance and treatment strategies for COVID-19 associated coagulopathy, perhaps even including tailored anticoagulation regimens or differences in vaccine deployment. In addition, more detailed investigations into socioeconomic factors, such as differences in housing environment or ease of access to health care, can aid not just in fighting the COVID-19 pandemic but also in increasing overall health equity.

Hospitalization and Mortality among Black Patients and White Patients with Covid-19

Acute Pulmonary Embolism and COVID-19

Coexistent COVID-19 pneumonia and pulmonary embolism: challenges in identifying dual pathology

Coagulation abnormalities and thrombosis in patients with COVID-19

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Pulmonary postmortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Venous thrombosis

The epidemiology of pulmonary embolism: racial contrasts in incidence and in-hospital case fatality

Racial differences in venous thromboembolism

Using a Federated Network of Real-World Data to Optimize Clinical Trials Operations

Behind the Numbers: Propensity Score Analysis-A Primer for the Diagnostic Radiologist

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

National Disparities in COVID-19 Outcomes between Black and White Americans

Pérez-Stable, COVID-19 and Racial/Ethnic Disparities

CDC Health Disparities and Inequalities Report -United States, 2013. Foreword, MMWR Suppl

Vital Signs: Racial Disparities in Age-Specific Mortality Among Blacks or African Americans -United States

Consortium, Presenting Characteristics, Comorbidities, and Outcomes Among

Patients Hospitalized With COVID-19 in the New York City Area

Cardiovascular Risk Factors and Venous Thromboembolism

Comparison of characteristics from White-and Black-Americans with venous thromboembolism: A cross-sectional study

Coagulation Status and Venous Thromboembolism Risk in African Americans: A Potential Risk Factor in COVID-19

Environmental and Genetic Risk Factors Associated with Venous Thromboembolism

African-American ethnicity is associated with higher plasma levels of D-dimer in adults with hypertension

D-Dimer in African Americans: Whole Genome Sequence Analysis and Relationship to Cardiovascular Disease Risk in the Jackson Heart Study

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

COVID-19 and African Americans

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.